Effect of aspirin on anti-platelet aggregation function in children with Kawasaki disease / 中国实用儿科杂志

ABSTRACT

OBJECTIVE: To evaluate the anti-platelet aggregation function of aspirin in children with Kawasaki disease(KD).METHODS: The clinical data of KD patients who was admitted to Capital Institute of Pediatrics-Peking University Teaching Hospital from September 2016 to September 2018 was retrospectively analyzed. All the children were treated with aspirin routinelyhigh-dose(30-50)mg/（kg·d)in acute stage and low-dose aspirin(3-5)mg/（kg·d)in the recovery period. Then the light transmission aggregometry(LTA)was used to determine the platelet aggregation rate of different doses of aspirin in order to evaluate the anti-platelet aggregation function,and the risk factors of aspirin resistance(AR)were analyzed by statistical method. RESULTS:(1)The platelet aggregation rate(AA%)after treatment with high-dose and low-dose aspirin in children with KD was 30.3%(1.2%,7.1%)and 2.9%(1.5%,60.4%),respectively,and there was no significant difference in platelet inhibition between different doses of aspirin(P=0.174).(2)The incidence of AR was 9.75%(23/236)in the highdose aspirin group and 8.05%(19/236)in the low-dose aspirin group. There was no significant difference in the incidence of AR between the two groups(P=0.617).(3)In the 19 children with AR and 217 children with aspirin sensitivity(AS)in oral low-dose aspirin treatment group,the age,sex,coagulation,biochemistry and other related indexes did not significantly differ between the two groups. CONCLUSION: The antiplatelet aggregation function of aspirin in KD children is not related to the dosage. AR is present in the treatment of Kawasaki disease,and the incidence of aspirin resistance is not related to dosage.